



## **Quantum-Si to Participate in B. Riley Securities' Life Sciences Tools Conference - Proteomics Setting the Blueprint for Innovative Drug Creation, Virtual Conference**

March 24, 2023

GUILFORD, Conn.--(BUSINESS WIRE)--Mar. 24, 2023-- [Quantum-Si Incorporated](#) (Nasdaq: QSI) ("Quantum-Si," "QSI" or the "Company"), The Protein Sequencing Company<sup>TM</sup>, today announced that it will be participating in B. Riley Securities' Life Sciences Tools Conference - Proteomics Setting the Blueprint for Innovative Drug Creation, Virtual Conference to be held on Thursday, April 6, 2023.

Patrick Schneider, Ph.D., Quantum-Si's President and Chief Operating Officer, will participate in the panel discussion "How to Translate Insights from Proteomics and Advances in AI into Drug Discovery and Innovation?" at 10:30 AM ET.

Additionally, Jeff Hawkins, Quantum-Si's Chief Executive Officer, and Dr. Schneider will participate in a fireside chat at 2:30 PM ET.

A link for live and archived webcasts of both events will be available in the "Investors" section of the Quantum-Si website under [Events & Presentations](#).

### **About Quantum-Si Incorporated**

Quantum-Si, The Protein Sequencing Company<sup>TM</sup>, is focused on revolutionizing the growing field of proteomics. The Company's suite of technologies is powered by a first-of-its-kind semiconductor chip designed to enable next-generation single-molecule protein sequencing and digitize proteomic research in order to advance drug discovery and diagnostics beyond what has been possible with DNA sequencing. Learn more at [www.quantum-si.com](http://www.quantum-si.com).

View source version on [businesswire.com](https://www.businesswire.com/news/home/20230324005113/en/): <https://www.businesswire.com/news/home/20230324005113/en/>

### **Investor**

Juan Avendano  
[ir@quantum-si.com](mailto:ir@quantum-si.com)

### **Media**

Michael Sullivan  
[media@quantum-si.com](mailto:media@quantum-si.com)

Source: Quantum-Si Incorporated